These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 9706046

  • 1. A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.
    Camenisch GP, Wang W, Wang B, Borchardt RT.
    Pharm Res; 1998 Aug; 15(8):1174-81. PubMed ID: 9706046
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability.
    Wang B, Wang W, Camenisch GP, Elmo J, Zhang H, Borchardt RT.
    Chem Pharm Bull (Tokyo); 1999 Jan; 47(1):90-5. PubMed ID: 9987829
    [Abstract] [Full Text] [Related]

  • 3. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
    Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, Borchardt RT.
    Pharm Res; 1999 Jan; 16(1):24-9. PubMed ID: 9950274
    [Abstract] [Full Text] [Related]

  • 4. Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide.
    Pauletti GM, Gangwar S, Okumu FW, Siahaan TJ, Stella VJ, Borchardt RT.
    Pharm Res; 1996 Nov; 13(11):1615-23. PubMed ID: 8956324
    [Abstract] [Full Text] [Related]

  • 5. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
    Gudmundsson OS, Nimkar K, Gangwar S, Siahaan T, Borchardt RT.
    Pharm Res; 1999 Jan; 16(1):16-23. PubMed ID: 9950273
    [Abstract] [Full Text] [Related]

  • 6. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
    Gudmundsson OS, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, Borchardt RT.
    Pharm Res; 1999 Jan; 16(1):7-15. PubMed ID: 9950272
    [Abstract] [Full Text] [Related]

  • 7. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
    Ouyang H, Tang F, Siahaan TJ, Borchardt RT.
    Pharm Res; 2002 Jun; 19(6):794-801. PubMed ID: 12134949
    [Abstract] [Full Text] [Related]

  • 8. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide.
    Pauletti GM, Gangwar S, Wang B, Borchardt RT.
    Pharm Res; 1997 Jan; 14(1):11-7. PubMed ID: 9034215
    [Abstract] [Full Text] [Related]

  • 9. Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties.
    He HT, Xu CR, Song X, Siahaan TJ.
    J Pept Res; 2003 Jun; 61(6):331-42. PubMed ID: 12753380
    [Abstract] [Full Text] [Related]

  • 10. A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics.
    Wang W, Camenisch G, Sane DC, Zhang H, Hugger E, Wheeler GL, Borchardt RT, Wang B.
    J Control Release; 2000 Mar 01; 65(1-2):245-51. PubMed ID: 10699284
    [Abstract] [Full Text] [Related]

  • 11. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z, Sun J, Chang Y, Liu Y, Fu Q, Xu Y, Sun Y, Pu X, Zhang Y, Jing Y, Yin S, Zhu M, Wang Y, He Z.
    Mol Pharm; 2011 Apr 04; 8(2):319-29. PubMed ID: 21280612
    [Abstract] [Full Text] [Related]

  • 12. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.
    Sudoh M, Pauletti GM, Yao W, Moser W, Yokoyama A, Pasternak A, Sprengeler PA, Smith AB, Hirschmann R, Borchardt RT.
    Pharm Res; 1998 May 04; 15(5):719-25. PubMed ID: 9619780
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
    Tang F, Borchardt RT.
    Pharm Res; 2002 Jun 04; 19(6):787-93. PubMed ID: 12134948
    [Abstract] [Full Text] [Related]

  • 14. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
    Schumacher-Klinger A, Fanous J, Merzbach S, Weinmüller M, Reichart F, Räder AFB, Gitlin-Domagalska A, Gilon C, Kessler H, Hoffman A.
    Mol Pharm; 2018 Aug 06; 15(8):3468-3477. PubMed ID: 29976060
    [Abstract] [Full Text] [Related]

  • 15. Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation.
    Song X, Xu CR, He HT, Siahaan TJ.
    Bioorg Chem; 2002 Aug 06; 30(4):285-301. PubMed ID: 12392707
    [Abstract] [Full Text] [Related]

  • 16. Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): comparison of in vitro and in vivo data.
    Kamm W, Raddatz P, Gante J, Kissel T.
    Pharm Res; 1999 Oct 06; 16(10):1527-33. PubMed ID: 10554093
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
    Tang F, Borchardt RT.
    Pharm Res; 2002 Jun 06; 19(6):780-6. PubMed ID: 12134947
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
    Ouyang H, Vander Velde DG, Borchardt RT, Siahaan TJ.
    J Pept Res; 2002 Apr 06; 59(4):183-95. PubMed ID: 11972752
    [Abstract] [Full Text] [Related]

  • 19. An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs.
    He X, Sugawara M, Kobayashi M, Takekuma Y, Miyazaki K.
    Int J Pharm; 2003 Sep 16; 263(1-2):35-44. PubMed ID: 12954178
    [Abstract] [Full Text] [Related]

  • 20. Optimizing oral absorption of peptides using prodrug strategies.
    Borchardt RT.
    J Control Release; 1999 Nov 01; 62(1-2):231-8. PubMed ID: 10518655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.